STOCK TITAN

[Form 4] Bristol-Myers Squibb Co. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Wendy Short Bartie, EVP Corporate Affairs of Bristol-Myers Squibb Company (BMY), reported securities transactions on Form 4 showing restricted stock units vesting and shares withheld for taxes. On 09/01/2025, 1,235 restricted stock units converted into 1,235 shares of common stock (reported as acquisition at $0) under a vesting schedule that began 09/01/2023 and vests in four equal installments. Simultaneously, 632 shares were withheld to satisfy tax-withholding obligations at an indicated price of $47.18 per share. After these events, Ms. Bartie directly beneficially owned 5,669 shares.

Wendy Short Bartie, EVP Corporate Affairs di Bristol-Myers Squibb Company (BMY), ha riportato transazioni su titoli nel Modulo 4 indicando che unità di azioni vincolate (RSU) sono maturate e azioni sono state trattenute per le imposte. In data 01/09/2025, 1.235 unità di azioni vincolate si sono convertite in 1.235 azioni ordinarie (segnalate come acquisizione a $0) secondo un piano di maturazione iniziato il 01/09/2023 e previsto in quattro rate uguali. Contemporaneamente, sono state trattenute 632 azioni per soddisfare gli obblighi di ritenuta fiscale al prezzo indicato di $47,18 per azione. Dopo queste operazioni, la Sig.ra Bartie possedeva direttamente beneficiariamente 5.669 azioni.

Wendy Short Bartie, EVP de Asuntos Corporativos de Bristol-Myers Squibb Company (BMY), informó transacciones de valores en el Formulario 4 indicando que unidades de acciones restringidas vencieron y se retuvieron acciones para impuestos. El 01/09/2025, 1.235 unidades de acciones restringidas se convirtieron en 1.235 acciones comunes (reportadas como adquisición a $0) bajo un calendario de adquisición iniciado el 01/09/2023 que vence en cuatro cuotas iguales. Simultáneamente, se retuvieron 632 acciones para cubrir obligaciones de retención fiscal al precio indicado de $47,18 por acción. Tras estos hechos, la Sra. Bartie poseía directamente y de forma beneficiaria 5.669 acciones.

브리스톨마이어스 스퀴브 컴퍼니(BMY) 기업담당 EVP인 Wendy Short Bartie는 양식 4에 증권 거래 내역을 보고하며 제한주식단위(RSU)가 성과지급되어 세금용으로 주식이 원천징수되었음을 알렸습니다. 2025-09-01에 1,235개의 제한주식단위가 1,235주의 보통주로 전환되었고(취득으로서 $0로 보고), 해당 단위는 2023-09-01에 시작되어 네 번에 걸쳐 균등하게 성과지급되는 베스팅 일정에 따라 처리되었습니다. 동시에 세금 원천징수를 위해 632주가 $47.18의 표시 가격으로 원천징수되었습니다. 이들 거래 후 Bartie 씨는 직접적으로 유익하게 5,669주를 보유하게 되었습니다.

Wendy Short Bartie, EVP Corporate Affairs de Bristol-Myers Squibb Company (BMY), a déclaré des opérations sur titres dans le formulaire 4 indiquant que des unités d'actions restreintes sont arrivées à échéance et que des actions ont été retenues pour impôts. Le 01/09/2025, 1 235 unités d'actions restreintes se sont converties en 1 235 actions ordinaires (déclarées comme acquisition à 0 $) selon un calendrier d'acquisition débutant le 01/09/2023 et s'échelonnant en quatre versements égaux. Simultanément, 632 actions ont été retenues pour satisfaire les obligations de retenue fiscale au prix indiqué de 47,18 $ par action. Après ces événements, Mme Bartie détenait directement et à titre bénéficiaire 5 669 actions.

Wendy Short Bartie, EVP Corporate Affairs bei Bristol-Myers Squibb Company (BMY), meldete Wertpapiergeschäfte im Formular 4 und gab an, dass Restricted Stock Units fällig wurden und Aktien zur Steuerabführung einbehalten wurden. Am 01.09.2025 wurden 1.235 Restricted Stock Units in 1.235 Stammaktien umgewandelt (als Erwerb zu $0 gemeldet) im Rahmen eines Vesting-Plans, der am 01.09.2023 begann und in vier gleichen Raten ausläuft. Gleichzeitig wurden 632 Aktien zur Erfüllung von Steuerabzugsverpflichtungen zum angegebenen Preis von $47,18 pro Aktie einbehalten. Nach diesen Vorgängen hielt Frau Bartie direkt wirtschaftlich berechtigt 5.669 Aktien.

Positive
  • Clear disclosure of RSU vesting, conversion ratio, and tax-withholding amount
  • Transaction labeled as compensation-related (vesting), indicating routine insider activity
Negative
  • None.

Insights

TL;DR: Routine insider vesting with tax withholding; not a market-moving trade.

The Form 4 discloses standard issuance of vested restricted stock units converting into 1,235 shares and 632 shares withheld to cover taxes at $47.18 per share. This is a non-discretionary, compensation-related transaction rather than an open-market purchase or sale intended to change ownership position. The net effect is a modest change in direct holdings to 5,669 shares, which is small relative to a large-cap issuer like BMY and unlikely to be material to investors.

TL;DR: Disclosure appears complete and compliant; transaction aligns with vesting schedule.

The filing indicates the RSUs vest in four equal installments beginning 09/01/2023 and each RSU converts into one share on vesting. Shares withheld for tax obligations are disclosed with price and amount. The form is signed by an attorney-in-fact, which is acceptable when authorized. No amendments or additional arrangements are disclosed.

Wendy Short Bartie, EVP Corporate Affairs di Bristol-Myers Squibb Company (BMY), ha riportato transazioni su titoli nel Modulo 4 indicando che unità di azioni vincolate (RSU) sono maturate e azioni sono state trattenute per le imposte. In data 01/09/2025, 1.235 unità di azioni vincolate si sono convertite in 1.235 azioni ordinarie (segnalate come acquisizione a $0) secondo un piano di maturazione iniziato il 01/09/2023 e previsto in quattro rate uguali. Contemporaneamente, sono state trattenute 632 azioni per soddisfare gli obblighi di ritenuta fiscale al prezzo indicato di $47,18 per azione. Dopo queste operazioni, la Sig.ra Bartie possedeva direttamente beneficiariamente 5.669 azioni.

Wendy Short Bartie, EVP de Asuntos Corporativos de Bristol-Myers Squibb Company (BMY), informó transacciones de valores en el Formulario 4 indicando que unidades de acciones restringidas vencieron y se retuvieron acciones para impuestos. El 01/09/2025, 1.235 unidades de acciones restringidas se convirtieron en 1.235 acciones comunes (reportadas como adquisición a $0) bajo un calendario de adquisición iniciado el 01/09/2023 que vence en cuatro cuotas iguales. Simultáneamente, se retuvieron 632 acciones para cubrir obligaciones de retención fiscal al precio indicado de $47,18 por acción. Tras estos hechos, la Sra. Bartie poseía directamente y de forma beneficiaria 5.669 acciones.

브리스톨마이어스 스퀴브 컴퍼니(BMY) 기업담당 EVP인 Wendy Short Bartie는 양식 4에 증권 거래 내역을 보고하며 제한주식단위(RSU)가 성과지급되어 세금용으로 주식이 원천징수되었음을 알렸습니다. 2025-09-01에 1,235개의 제한주식단위가 1,235주의 보통주로 전환되었고(취득으로서 $0로 보고), 해당 단위는 2023-09-01에 시작되어 네 번에 걸쳐 균등하게 성과지급되는 베스팅 일정에 따라 처리되었습니다. 동시에 세금 원천징수를 위해 632주가 $47.18의 표시 가격으로 원천징수되었습니다. 이들 거래 후 Bartie 씨는 직접적으로 유익하게 5,669주를 보유하게 되었습니다.

Wendy Short Bartie, EVP Corporate Affairs de Bristol-Myers Squibb Company (BMY), a déclaré des opérations sur titres dans le formulaire 4 indiquant que des unités d'actions restreintes sont arrivées à échéance et que des actions ont été retenues pour impôts. Le 01/09/2025, 1 235 unités d'actions restreintes se sont converties en 1 235 actions ordinaires (déclarées comme acquisition à 0 $) selon un calendrier d'acquisition débutant le 01/09/2023 et s'échelonnant en quatre versements égaux. Simultanément, 632 actions ont été retenues pour satisfaire les obligations de retenue fiscale au prix indiqué de 47,18 $ par action. Après ces événements, Mme Bartie détenait directement et à titre bénéficiaire 5 669 actions.

Wendy Short Bartie, EVP Corporate Affairs bei Bristol-Myers Squibb Company (BMY), meldete Wertpapiergeschäfte im Formular 4 und gab an, dass Restricted Stock Units fällig wurden und Aktien zur Steuerabführung einbehalten wurden. Am 01.09.2025 wurden 1.235 Restricted Stock Units in 1.235 Stammaktien umgewandelt (als Erwerb zu $0 gemeldet) im Rahmen eines Vesting-Plans, der am 01.09.2023 begann und in vier gleichen Raten ausläuft. Gleichzeitig wurden 632 Aktien zur Erfüllung von Steuerabzugsverpflichtungen zum angegebenen Preis von $47,18 pro Aktie einbehalten. Nach diesen Vorgängen hielt Frau Bartie direkt wirtschaftlich berechtigt 5.669 Aktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Short Bartie Wendy

(Last) (First) (Middle)
BRISTOL-MYERS SQUIBB COMPANY
ROUTE 206 & PROVINCE LINE ROAD

(Street)
PRINCETON NJ 08543

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Corporate Affairs
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.10 par value 09/01/2025 M 1,235(1) A $0 6,301 D
Common Stock, $0.10 par value 09/01/2025 F 632(2) D $47.18 5,669 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (3) 09/01/2025 M 1,235 (1) 09/01/2026 Common Stock, $0.10 par value 1,235 $0 1,236 D
Explanation of Responses:
1. These restricted stock units vest in four equal installments beginning on September 1, 2023.
2. Shares withheld for payment of taxes upon vesting of awards.
3. Each restricted stock unit converts into one share of common stock upon vesting.
Remarks:
/s/ Sophie M. Bail, attorney-in-fact for Wendy Short Bartie 09/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Wendy Short Bartie report on Form 4 for BMY?

The filing reports conversion of 1,235 restricted stock units into 1,235 shares on 09/01/2025 and 632 shares withheld to pay taxes at $47.18 per share.

How many shares does Wendy Short Bartie beneficially own after the transactions?

After the reported transactions, she beneficially owns 5,669 shares directly.

Were these transactions open-market trades or vesting-related?

These were vesting-related transactions: RSUs converting to shares and shares withheld for tax withholding, not open-market purchases or discretionary sales.

When did the RSU vesting schedule begin and how do RSUs convert?

The RSU vesting schedule began on 09/01/2023, vests in four equal installments, and each RSU converts into one share upon vesting.

Who signed the Form 4 filing for Wendy Short Bartie?

The form was signed by Sophie M. Bail, attorney-in-fact, on 09/03/2025.
Bristol-Myers Squibb Co

NYSE:BMY

BMY Rankings

BMY Latest News

BMY Latest SEC Filings

BMY Stock Data

96.03B
2.03B
0.08%
82.89%
1.52%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
PRINCETON